Formulation of human antibodies for treating tnf-alpha associated disorders

Formulation of human antibodies for treating tnf-alpha associated disorders

  • CN 102,078,608 A
  • Filed: 08/15/2003
  • Published: 06/01/2011
  • Est. Priority Date: 08/16/2002
  • Status: Active Application
First Claim
Patent Images

1. pharmaceutical preparation that is selected from down group:

  • (a) liquid aqueous pharmaceutical preparation comprises the antibody of the treatment effective dose that is present in the buffer, and the pH of said preparation is about 4-8, and the shelf-life was at least 18 months;

    (b) aqueous medicament preparations comprises the antibody of the treatment effective dose that is present in the buffer, and the pH of said preparation is about 4-8, and the shelf-life under liquid condition was at least 18 months;

    (c) liquid aqueous pharmaceutical preparation comprises the antibody of the treatment effective dose that is present in the buffer, and the pH of said preparation is about 4-8, and described preparation keeps stable can freeze/melt circulation at least 3 times after;

    With(d) liquid aqueous pharmaceutical preparation comprises the antibody of the treatment effective dose that is present in the buffer, and the pH of said preparation is 4-8, and has at least 12 months enhanced stability under 2-8 ℃

    temperature.

View all claims
    ×
    ×

    Thank you for your feedback

    ×
    ×